ZA201807031B - Fulvestrant formulations and methods of their use - Google Patents
Fulvestrant formulations and methods of their useInfo
- Publication number
- ZA201807031B ZA201807031B ZA2018/07031A ZA201807031A ZA201807031B ZA 201807031 B ZA201807031 B ZA 201807031B ZA 2018/07031 A ZA2018/07031 A ZA 2018/07031A ZA 201807031 A ZA201807031 A ZA 201807031A ZA 201807031 B ZA201807031 B ZA 201807031B
- Authority
- ZA
- South Africa
- Prior art keywords
- microns
- less
- methods
- formulations
- fulvestrant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332842P | 2016-05-06 | 2016-05-06 | |
| US201662420555P | 2016-11-10 | 2016-11-10 | |
| PCT/US2017/031376 WO2017193048A1 (en) | 2016-05-06 | 2017-05-05 | Fulvestrant formulations and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201807031B true ZA201807031B (en) | 2023-10-25 |
Family
ID=58709642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/07031A ZA201807031B (en) | 2016-05-06 | 2018-10-22 | Fulvestrant formulations and methods of their use |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190134059A1 (OSRAM) |
| EP (1) | EP3452011A1 (OSRAM) |
| JP (3) | JP2019516789A (OSRAM) |
| KR (1) | KR102438425B1 (OSRAM) |
| CN (1) | CN109310621A (OSRAM) |
| AU (2) | AU2017261321B2 (OSRAM) |
| CA (1) | CA3022834A1 (OSRAM) |
| CO (1) | CO2018013257A2 (OSRAM) |
| IL (2) | IL285928B2 (OSRAM) |
| MA (1) | MA44862A (OSRAM) |
| MX (2) | MX2018013414A (OSRAM) |
| MY (1) | MY205661A (OSRAM) |
| UA (1) | UA125514C2 (OSRAM) |
| WO (1) | WO2017193048A1 (OSRAM) |
| ZA (1) | ZA201807031B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| BR112020009141A2 (pt) | 2017-11-08 | 2020-10-27 | Eagle Pharmaceuticals, Inc. | método para tratar câncer de mama num indivíduo |
| US12377049B2 (en) * | 2019-12-11 | 2025-08-05 | Shanghai Bocimed Pharmaceutical Co., Ltd. | Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof |
| CN113694017B (zh) * | 2020-05-11 | 2024-04-02 | 鲁南制药集团股份有限公司 | 一种氟维司群注射制剂及其制备方法 |
| WO2022100750A1 (zh) * | 2020-11-16 | 2022-05-19 | 北京厚燊维康科技有限责任公司 | 可用于光动力治疗或诊断的制剂 |
| CN120284882A (zh) * | 2020-12-10 | 2025-07-11 | 上海云晟研新生物科技有限公司 | 氟维司群药物组合物、其制备方法及应用 |
| JP2024545690A (ja) * | 2021-12-20 | 2024-12-10 | サムヤン、ホールディングス、コーポレーション | 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法 |
| KR20240105964A (ko) * | 2022-12-29 | 2024-07-08 | 주식회사 삼양홀딩스 | 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| JP2003533464A (ja) | 2000-05-15 | 2003-11-11 | フアルマシア・イタリア・エツセ・ピー・アー | 安定化ステロイド懸濁液 |
| GB0116619D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| IL159576A0 (en) * | 2001-07-07 | 2004-06-01 | Astrazeneca Ab | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| JP2003298516A (ja) | 2002-03-29 | 2003-10-17 | Fujitsu Ltd | 波長分散補償装置 |
| WO2006013369A2 (en) | 2004-08-04 | 2006-02-09 | Camurus Ab | Compositions forming non-lamellar dispersions |
| MX2007013914A (es) | 2005-05-09 | 2008-02-22 | Biosphere Medical S A | Composiciones y metodos que usan microesferas y agentes de contraste no ionicos. |
| WO2007069272A2 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN101108168B (zh) * | 2007-08-03 | 2010-12-08 | 西安力邦医药科技有限责任公司 | 一种氟维司群缓释微球的制备方法 |
| ES2731881T3 (es) | 2007-09-25 | 2019-11-19 | Formulex Pharma Innovations Ltd | Composiciones que comprenden compuestos activos lipófilos y método para su preparación |
| CN102014925B (zh) | 2008-03-07 | 2013-02-06 | 赛多斯有限责任公司 | 氟维司群配制剂 |
| TW201016220A (en) * | 2008-10-31 | 2010-05-01 | Scinopharm Taiwan Ltd | Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof |
| JP2012530704A (ja) | 2009-06-18 | 2012-12-06 | アボット・ラボラトリーズ | 安定なナノ粒子状薬物懸濁液 |
| EP2460539A4 (en) * | 2009-07-31 | 2013-12-04 | Xi An Libang Medical Technology Co Ltd | MEDICAMENT IN THE FORM OF NANO OR MICROBALLS, METHOD FOR THE PRODUCTION THEREOF AND COMPOSITION THEREOF AND USE THEREOF |
| WO2011022861A1 (zh) * | 2009-08-31 | 2011-03-03 | 西安力邦医药科技有限责任公司 | 氟维司群纳米球/微球及其制备方法和用途 |
| WO2012021791A2 (en) | 2010-08-13 | 2012-02-16 | Scidose Llc | Aqueous formulation with improved stability |
| EA201300341A1 (ru) * | 2010-09-16 | 2013-09-30 | Шимода Байотек (Пти) Лтд. | Композиция фулвестранта и способы применения |
| EP2468258A1 (en) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| CA2824063C (en) | 2011-01-09 | 2020-02-18 | Anp Technologies, Inc. | Hydrophobic molecule-induced branched polymer aggregates and their use |
| US9029582B2 (en) * | 2011-05-20 | 2015-05-12 | Capital, Business Y Gestion De Finanzas S.L. | Pharmaceutical composition |
| CN102915088A (zh) | 2011-08-03 | 2013-02-06 | 鸿富锦精密工业（深圳）有限公司 | 资料存储器固定装置 |
| WO2013153559A1 (en) | 2012-04-09 | 2013-10-17 | Scidose, Llc | Fulvestrant formulations |
| US11179468B2 (en) * | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| SG10201706196XA (en) | 2012-06-08 | 2017-08-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| JP2016529308A (ja) * | 2013-09-06 | 2016-09-23 | サラー ウッディン アハメド， | フルベストラント組成物 |
| CA2925523A1 (en) * | 2013-10-03 | 2015-04-09 | Millenium Pharmaceuticals, Inc. | Enhanced treatment regimens using pi3k.alpha. inhibitors |
| HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| PT107433B (pt) | 2014-01-28 | 2018-12-04 | Hovione Farm S A | Processo de redução e controlo do tamanho de partícula |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| WO2016004369A1 (en) | 2014-07-02 | 2016-01-07 | The Research Foundation For The State University Of New York | Surfactant-stripped micelle compositions with high cargo to surfactant ratio |
| CN104434808A (zh) | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种治疗性纳米粒子及其制备方法 |
-
2017
- 2017-05-04 IL IL285928A patent/IL285928B2/en unknown
- 2017-05-05 EP EP17723902.7A patent/EP3452011A1/en active Pending
- 2017-05-05 MX MX2018013414A patent/MX2018013414A/es unknown
- 2017-05-05 CN CN201780027809.5A patent/CN109310621A/zh active Pending
- 2017-05-05 US US16/099,265 patent/US20190134059A1/en not_active Abandoned
- 2017-05-05 KR KR1020187034942A patent/KR102438425B1/ko active Active
- 2017-05-05 UA UAA201812019A patent/UA125514C2/uk unknown
- 2017-05-05 MA MA044862A patent/MA44862A/fr unknown
- 2017-05-05 AU AU2017261321A patent/AU2017261321B2/en active Active
- 2017-05-05 JP JP2019510578A patent/JP2019516789A/ja active Pending
- 2017-05-05 WO PCT/US2017/031376 patent/WO2017193048A1/en not_active Ceased
- 2017-05-05 MY MYPI2018703903A patent/MY205661A/en unknown
- 2017-05-05 CA CA3022834A patent/CA3022834A1/en active Pending
-
2018
- 2018-10-18 IL IL262465A patent/IL262465A/en unknown
- 2018-10-22 ZA ZA2018/07031A patent/ZA201807031B/en unknown
- 2018-11-01 MX MX2022013199A patent/MX2022013199A/es unknown
- 2018-12-06 CO CONC2018/0013257A patent/CO2018013257A2/es unknown
-
2021
- 2021-07-19 JP JP2021118471A patent/JP7312523B2/ja active Active
- 2021-07-19 US US17/379,534 patent/US12370199B2/en active Active
-
2023
- 2023-05-26 JP JP2023086732A patent/JP2023109959A/ja active Pending
- 2023-05-31 AU AU2023203392A patent/AU2023203392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ747911A (en) | 2025-03-28 |
| IL262465A (en) | 2018-12-31 |
| JP2023109959A (ja) | 2023-08-08 |
| IL285928B1 (en) | 2025-02-01 |
| MA44862A (fr) | 2019-03-13 |
| AU2017261321B2 (en) | 2023-03-09 |
| MX2022013199A (es) | 2022-12-13 |
| US20210346396A1 (en) | 2021-11-11 |
| MX2018013414A (es) | 2019-06-06 |
| JP7312523B2 (ja) | 2023-07-21 |
| JP2019516789A (ja) | 2019-06-20 |
| RU2018142068A (ru) | 2020-06-08 |
| CN109310621A (zh) | 2019-02-05 |
| KR20190005183A (ko) | 2019-01-15 |
| UA125514C2 (uk) | 2022-04-13 |
| IL285928A (en) | 2021-10-31 |
| AU2023203392A1 (en) | 2023-06-29 |
| MY205661A (en) | 2024-11-04 |
| EP3452011A1 (en) | 2019-03-13 |
| KR102438425B1 (ko) | 2022-09-01 |
| CO2018013257A2 (es) | 2018-12-28 |
| BR112018072768A2 (pt) | 2019-02-19 |
| JP2021169510A (ja) | 2021-10-28 |
| CA3022834A1 (en) | 2017-11-09 |
| WO2017193048A1 (en) | 2017-11-09 |
| US20190134059A1 (en) | 2019-05-09 |
| IL285928B2 (en) | 2025-06-01 |
| AU2017261321A1 (en) | 2018-11-15 |
| RU2018142068A3 (OSRAM) | 2020-09-17 |
| US12370199B2 (en) | 2025-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013199A (es) | Formulaciones de fulvestrant y metodos para su uso. | |
| ZA202206078B (en) | Anti-cd3 antibodies and methods of use | |
| MX2023008559A (es) | Proteínas de fusión fc heterodiméricas il15/il15ra. | |
| MY195442A (en) | Anti-CD40 Antibodies and Their Uses | |
| MY191169A (en) | Anti-fcrh5 antibodies | |
| TWD208426S (zh) | 鼻管組合及其配件 | |
| PH12020551710A1 (en) | Anti-hla-g antibodies and use thereof | |
| MX2021014956A (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos. | |
| MX2020009461A (es) | Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso. | |
| SG10201809668TA (en) | Anti-her2 antibodies and immunoconjugates | |
| EP4234689A3 (en) | Split inteins with exceptional splicing activity | |
| SG10201804931QA (en) | Anti-cll-1 antibodies and immunoconjugates | |
| HK1222205A1 (zh) | 由多能干细胞产生的光感受器和光感受器袓细胞 | |
| MX390083B (es) | Formulaciones de (r)-2-amino-3-fenilpropil carbamato. | |
| WO2016061389A3 (en) | Anti-alpha-synuclein antibodies and methods of use | |
| EP4295911A3 (en) | Humanized anti-complement factor c1q antibodies and uses thereof | |
| EP4351045A3 (en) | Methods and apparatus for setting subband csi-related parameters | |
| AU2014233478A8 (en) | Anti-CD25 antibodies and their uses | |
| MY194603A (en) | Anti-Complement Factor Bb Antibodies And Uses Thereof | |
| TWD189563S (zh) | 鼻管組件 | |
| EP4252681A3 (en) | Implantable objects, guiding devices, and methods of use thereof | |
| WO2019183215A3 (en) | Halloysite-based nanocomposites and methods of making and using the same | |
| PH12018502556A1 (en) | Cosmetic base including amide alcohol, and cosmetic | |
| MX2018016417A (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas. | |
| GEP20186893B (en) | Pyrazines modulators of gpr6 |